| Dr Chelsea Katelyn Popp, DNP, CRNP, FNP-C | |
|
301 E 18th St, Anniston, AL 36207-3952 | |
| (256) 235-8900 | |
| Not Available |
| Full Name | Dr Chelsea Katelyn Popp |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 301 E 18th St, Anniston, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306338298 | NPI | - | NPPES |
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
While authorities in Uttar Pradesh are narrowing down on dengue as the 'mystery disease' behind the deaths of more than 50 people, mostly children, in the last fortnight, they are not ruling out scrub typhus or other monsoon-related infections.
When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
| Entity Name | Dr. Tamara Mcintosh Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467549147 PECOS PAC ID: 9436158391 Enrollment ID: O20061204000546 |
News Archive
While authorities in Uttar Pradesh are narrowing down on dengue as the 'mystery disease' behind the deaths of more than 50 people, mostly children, in the last fortnight, they are not ruling out scrub typhus or other monsoon-related infections.
When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
While authorities in Uttar Pradesh are narrowing down on dengue as the 'mystery disease' behind the deaths of more than 50 people, mostly children, in the last fortnight, they are not ruling out scrub typhus or other monsoon-related infections.
When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
| Entity Name | Alabama Physicians Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750062527 PECOS PAC ID: 2668835604 Enrollment ID: O20230824000442 |
News Archive
While authorities in Uttar Pradesh are narrowing down on dengue as the 'mystery disease' behind the deaths of more than 50 people, mostly children, in the last fortnight, they are not ruling out scrub typhus or other monsoon-related infections.
When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chelsea Katelyn Popp, DNP, CRNP, FNP-C 1325 Quintard Ave, Anniston, AL 36201-4619 Ph: (256) 741-1339 | Dr Chelsea Katelyn Popp, DNP, CRNP, FNP-C 301 E 18th St, Anniston, AL 36207-3952 Ph: (256) 235-8900 |
News Archive
While authorities in Uttar Pradesh are narrowing down on dengue as the 'mystery disease' behind the deaths of more than 50 people, mostly children, in the last fortnight, they are not ruling out scrub typhus or other monsoon-related infections.
When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company's Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.
Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
› Verified 5 days ago